Form 4: Maze Therapeutics Executive Sells Shares

Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised stock options and sold 25,156 shares of common stock for a significant profit.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc. (MAZE), reported transactions involving the company's securities.
• On January 7, 2026, Mr. Bernstein exercised stock options to acquire 25,156 shares of common stock at an exercise price of $10.42 per share.
• Concurrently, on January 7, 2026, Mr. Bernstein sold all 25,156 newly acquired shares of common stock at a weighted average price of $40.2011 per share.
• The sales occurred in multiple transactions with prices ranging from $40.00 to $40.55 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Bernstein on September 29, 2025.
• Following these transactions, Mr. Bernstein beneficially owns 0 shares of common stock directly.
• Mr. Bernstein still holds 312,407 derivative securities in the form of stock options.
• The exercised option vested as to 1/4th of the total award on October 3, 2023, and thereafter vests as to 1/48th of the total award on the monthly anniversary, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While an executive selling shares can sometimes be viewed negatively, this was a pre-planned transaction (10b5-1) to monetize vested options, indicating the executive realized a significant gain, which reflects positively on the company's stock performance. It's a routine event for executives.

Positives

• The executive realized a substantial profit from the exercise and sale of options, indicating a significant increase in the company's stock value since the options were granted.
• The transaction was pre-planned under a Rule 10b5-1 trading plan, suggesting a systematic approach to managing personal holdings rather than a reaction to new, negative information.

Negatives

• An insider sale, even if planned, removes shares from the executive's direct beneficial ownership, which some investors might interpret as a lack of conviction, though it is a common practice for executives to monetize vested options.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction report (Form 4) for an executive at a biotechnology company. Such transactions are common as executives monetize vested equity compensation. The significant profit realized by the executive reflects the growth in the company's stock value, which is generally positive for the biotechnology sector where stock performance is often tied to development milestones and market perception.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a standard practice among executives in publicly traded companies across all industries, including biotechnology, to manage personal stock sales in compliance with insider trading regulations.
• The profit margin on the option exercise and sale (approximately 285% from exercise price to sale price) is indicative of strong stock performance, which can be compared to the performance of peer biotechnology companies over the same period. Without specific peer data, a direct comparison is not possible, but such gains are not uncommon in successful biotech ventures.

Corporate Governance

Stakeholder Impact

• Shareholders: The executive's profitable sale of shares demonstrates value creation, potentially reinforcing confidence in the company's stock performance. However, some may view any insider selling as a slight negative, regardless of the 10b5-1 plan.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Maze Therapeutics, MAZE, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Harold Bernstein, Biotechnology, Executive Compensation